We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+5.57%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$277M
AUM Growth
-$20.9M
Cap. Flow
-$20.6M
Cap. Flow %
-7.41%
Top 10 Hldgs %
84.21%
Holding
28
New
6
Increased
8
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
EOLS icon
Evolus
EOLS
+$33.9M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$30.3M
3
QDEL icon
QuidelOrtho
QDEL
+$29.8M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$7.89M
5
SCYX icon
SCYNEXIS
SCYX
+$7.29M

Top Sells

Rank Stock Value
1
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$91.5M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$27.4M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$7.99M
4
DVAX
Dynavax Technologies
DVAX
+$4.09M
5
CSTL icon
Castle Biosciences
CSTL
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APEN
26
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-370,000
Closed -$3.67M
CFMS
27
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-402,651
Closed -$648K
CTIC
28
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-6,535,674
Closed -$27.4M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Stonepine Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Stonepine Capital Management held 28 positions worth $277M, down 7% from $298M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Stonepine Capital Management withdrew a net $20.6M in Q2 2023, closing 7 positions and reducing 7 holdings. Its most notable exit was Amryt Pharma plc American Depositary Shares, an estimated $91.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Amylyx Pharmaceuticals worth $24.2M.

  • Stonepine Capital Management's largest Q2 2023 buy was Amylyx Pharmaceuticals: 1,121,028 shares worth $24.2M.
  • Stonepine Capital Management added most to Evolus in Q2 2023, an estimated $33.9M increase.
  • Stonepine Capital Management's biggest Q2 2023 reduction was Xeris Biopharma Holdings, cutting an estimated $7.99M.
  • Stonepine Capital Management fully exited Amryt Pharma plc American Depositary Shares in Q2 2023, selling an estimated $91.5M.
  • Stonepine Capital Management's ten largest holdings make up 84% of its $277M portfolio in Q2 2023.
  • Stonepine Capital Management opened 6 new positions and closed 7 in Q2 2023.
  • Stonepine Capital Management's portfolio value fell 7% quarter-over-quarter to $277M.

Based on Stonepine Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.